MedicineEurope PMC
Heuristic editor, no API keyVerdict: NotableHealthcare spending and factors associated with fall injury in Australia residential aged care: a cohort analysis
Background Given that fall injury is a critical public health concern in Australia, understanding the economic implications of falls among older adults is crucial to allocating healthcare resources efficiently to…
Key numbers
- 20% of the 2021-2022 healthcare
VerdictWorth a reader's time today.
Abstract
Background Given that fall injury is a critical public health concern in Australia, understanding the economic implications of falls among older adults is crucial to allocating healthcare resources efficiently to reduce falls and improve quality of life. This study therefore aimed to estimate the cost and identify factors associated with fall-related injuries within residential aged care (RAC). Methods A cohort analysis from the healthcare system perspective based on data from a double-blinded randomised controlled trial-the Opti-Med trial. The trial participants were 303 people aged ≥65 years. Identification of in-scope data from the trial dataset was achieved using the falls description note and the National Hospital Cost Data Collection diagnostic related group classification system. Data analyses were performed using STATA V.17. All costs were adjusted to 2022 Australian dollars. Results On average, the cost of an injurious fall per incident was 2494 (SD=6199), while the average cost of falls per resident annum was 1798 (SD=6002). The potential cost of injurious falls per annum in Australia's RAC system was $325 million. Sex and body mass index (BMI) were identified factors associated with fall injury. There was an inverted U-shaped relationship between BMI and falls risk in RAC. Conclusions The healthcare spending on fall injury per resident annum in RAC represents 20% of the 2021-2022 healthcare expenditure per capita. The high cost and inverted U-shaped relationship between BMI and falls risk underscores the need for more effective and RAC-tailored falls prevention strategies in this setting. Trial registration numbers Australian New Zealand Clinical Trial Registry (ACTRN12613001204730); WHO Universal Trial (U1111-1148-6094).
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ███░░ 3 | 10% | A method or resource many groups across the field will adopt within a year. |
| Magnitude | ██░░░ 2 | 20% | Solid incremental gain on a meaningful problem. |
| Evidence | ████░ 4 | 32% | Strong: large scale, preregistered, independently replicated, or a well-powered randomized trial. |
| Novelty | ██░░░ 2 | 8% | A new combination of known ideas. |
| Trajectory | ███░░ 3 | 5% | A clear path to scale. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: breadth (general-purpose); novelty (open problem); design (randomized, blinded); scale (efficient); stakes (global scale, prevention or cure).
How the score was computed
- Merit
- 6.1 / 10
- Adjusted merit
- 4.9 / 10
- Attention
- 35%
- Freshness
- 84%
- Citations2 (reference 20, via europepmc, Sep 30, 2026, 11:05 UTC)
- Field-weighted citation impact4.0 (reference 3, via openalex, Sep 30, 2026, 11:05 UTC)